|Personal & Precise|
The Continued Push Toward Targeted Therapies
In his recent State of the Union address and again a few days later at the White House, President Barack Obama outlined his $215 million Precision Medicine Initiative.
|Best Case Scenarios|
CorrectChemo Measures Cancer’s Response to Therapeutic Agents
While the patented technology might be complex, the premise behind it is straightforward … not every chemotherapy agent is equal in every patient.
|By the Numbers: The Latest Stats on Cancer|
Death rates down, more work awaits
As the ‘official sponsor of birthdays,’ the American Cancer Society (ACS) found a reason to rejoice in their latest report – Cancer Facts & Figures 2015.
|ONcology Rounds: Prostate Cancer|
Urology Associates Offering New Fusion Biopsy
Urology Associates, PC, introduced targeted MR/US fusion biopsy in late January, becoming the first urology practice in the state to offer the new technology to patients with elevated and/or rising PSA levels.
|ONcology Rounds: Breast Cancer|
New Drug Seen as Possible ‘Game Changer’
Last month, Pfizer Inc. received Food and Drug Administration accelerated approval of Ibrance® (palbociclib) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer as first-line endocrine-based therapy for their metastatic disease.